ChemoCentryx, Inc. (NASDAQ:CCXI)‘s stock had its “hold” rating restated by Cowen and Company in a research report issued on Tuesday, August 8th.
The analysts wrote, “ChemoCentryx reported Q2 financials, including a net loss of $9.2MM and a June 30.””
Separately, Zacks Investment Research raised ChemoCentryx from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a report on Monday, July 17th.
Shares of ChemoCentryx (NASDAQ:CCXI) traded down 1.72% on Tuesday, reaching $6.87. The company had a trading volume of 141,943 shares. The company’s 50-day moving average price is $9.33 and its 200-day moving average price is $7.71. ChemoCentryx has a 52-week low of $4.17 and a 52-week high of $10.80. The firm’s market capitalization is $334.61 million.
ChemoCentryx (NASDAQ:CCXI) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by $0.02. The business had revenue of $8.94 million during the quarter. On average, analysts predict that ChemoCentryx will post ($0.90) earnings per share for the current year.
In other news, insider Petrus Bekker sold 30,000 shares of the company’s stock in a transaction on Wednesday, July 12th. The stock was sold at an average price of $9.98, for a total transaction of $299,400.00. Following the completion of the sale, the insider now directly owns 65,963 shares in the company, valued at approximately $658,310.74. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders have sold 223,649 shares of company stock valued at $2,157,360. Corporate insiders own 26.80% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. P.A.W. Capital Corp increased its stake in shares of ChemoCentryx by 33.3% in the first quarter. P.A.W. Capital Corp now owns 160,000 shares of the biopharmaceutical company’s stock valued at $1,165,000 after buying an additional 40,000 shares in the last quarter. TIAA CREF Investment Management LLC increased its stake in shares of ChemoCentryx by 37.5% in the first quarter. TIAA CREF Investment Management LLC now owns 128,546 shares of the biopharmaceutical company’s stock valued at $936,000 after buying an additional 35,049 shares in the last quarter. Spark Investment Management LLC acquired a new stake in shares of ChemoCentryx during the first quarter valued at $1,050,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of ChemoCentryx during the first quarter valued at $189,000. Finally, Eagle Global Advisors LLC acquired a new stake in shares of ChemoCentryx during the first quarter valued at $337,000. Institutional investors and hedge funds own 49.37% of the company’s stock.
ChemoCentryx Company Profile
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.